HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Good ‘Fit’ For Regulation Shifting US FDA's ODSP Into Larger Food Safety Program – Director

Executive Summary

ODSP Director Cara Welch spoke about food programs structure and other supplement industry regulatory news days before first day on the job for agency’s first deputy commissioner for human foods, a post added in the human foods reorganization plan.

You may also be interested in...



US FDA Regulatory Affairs Reorg To Include Inspectors Trained In Real-World Evidence – Califf

The US FDA Commissioner acknowledged that the inspectorate has not been prepared for RWE, but as part of the revamp, a dedicated team will encourage its use “when it’s appropriate.”

US FDA’s First Deputy Commissioner For Foods Studied For Post In Agency’s External Review

James Jones had 30-year career at the EPA before participating in the Reagan-Udall Foundation’s review of FDA’s food safety programs, reaching deep into agency’s current structural and operational norms to suggest far-reaching changes.

US FDA’s Human Foods Program Reorganization Plan Isn’t Palatable To Supplement Industry

Reorganization of CFSAN and related ORA operations into “unified Human Foods Program” would move ODSP into Office of Food Chemical Safety, Dietary Supplements and Innovation. Stakeholders plan to influence agency against making the change, or sway lawmakers to object, similar to what they did pushing for ODSP’s establishment less than 10 years ago.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154039

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel